---
title: "Weigao Group Flags Orthopaedic Unit Disclosure on Shanghai Exchange"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280817528.md"
description: "Shandong Weigao Group Medical Polymer Co, a Hong Kong-listed medical device maker, announced that its orthopaedic subsidiary has disclosed information on the Shanghai Stock Exchange, complying with listing rules in both PRC and Hong Kong. This move emphasizes the company's commitment to regulatory transparency and consistent communication with investors across markets. The latest analyst rating for the stock (HK:1066) is a Hold with a price target of HK$5.50, and the company has a market cap of HK$20.08B."
datetime: "2026-03-27T15:20:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280817528.md)
  - [en](https://longbridge.com/en/news/280817528.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280817528.md)
---

# Weigao Group Flags Orthopaedic Unit Disclosure on Shanghai Exchange

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Shandong Weigao Group Medical Polymer Co ( (HK:1066) ) has provided an announcement.

Shandong Weigao Group Medical Polymer Company Limited, a Hong Kong-listed Chinese medical device maker specializing in polymer-based products, oversees a broad portfolio that includes its orthopaedic subsidiary, Shandong Weigao Orthopaedic Device Company Limited. The group’s dual listings in Hong Kong and Shanghai highlight its integration into both domestic and international capital markets.

The company announced that, in compliance with PRC and Hong Kong listing rules, its orthopaedic subsidiary has published an announcement on the Shanghai Stock Exchange’s website, with a corresponding notice posted on the Hong Kong exchange’s Chinese-language site. This move underscores the group’s ongoing regulatory transparency obligations and coordination between its mainland and Hong Kong listings, ensuring consistent information for investors across markets.

The most recent analyst rating on (HK:1066) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

**More about Shandong Weigao Group Medical Polymer Co**

Shandong Weigao Group Medical Polymer Company Limited is a PRC-incorporated medical device manufacturer focused on polymer-based medical products. Listed in Hong Kong under stock code 1066, the group also has an orthopaedic device subsidiary listed in Shanghai, reflecting a diversified presence across key Chinese capital markets in the healthcare sector.

**Average Trading Volume:** 15,774,087

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$20.08B

For a thorough assessment of 1066 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [01066.HK](https://longbridge.com/en/quote/01066.HK.md)
- [688161.CN](https://longbridge.com/en/quote/688161.CN.md)
- [159883.CN](https://longbridge.com/en/quote/159883.CN.md)
- [159898.CN](https://longbridge.com/en/quote/159898.CN.md)
- [562600.CN](https://longbridge.com/en/quote/562600.CN.md)

## Related News & Research

- [Broncus shareholders back all AGM resolutions, update articles of association](https://longbridge.com/en/news/286439966.md)
- [Basecare Wins NMPA Class III Approval for Gems Embryo Culture Medium](https://longbridge.com/en/news/286258287.md)
- [Shandong Weigao Sets Up Korea-Focused Fund in Connected Deal](https://longbridge.com/en/news/284802061.md)
- [DOJ Launches Criminal Probe Into Blue State Hospital](https://longbridge.com/en/news/286157785.md)
- [Island Pharmaceuticals Strengthens Biodefence Engagement for Galidesivir Advancement](https://longbridge.com/en/news/286834766.md)